DALLAS, TX--(Marketwired - Mar 22, 2017) - TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, today announced that its founder and CSO, Dr. Kevin Nelson, will participate in a BioPharma Dealmakers webcast featuring five companies' innovative drug delivery technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 11:00 am EDT on March 29th. Register here.
This webcast will highlight how innovative new approaches to biologic and pharmaceutical delivery may enable breakthroughs in oncology, treatment of CNS diseases and women's health. Presented technologies will include fiber-based drug delivery for implantable and topical devices, digitally controlled needle-free devices, sustained and controlled transdermal delivery technology, targeted penetration matrix technology for non-invasive delivery and location-specific nano machines for chemotherapy payload delivery.
TissueGen's ELUTE fiber may directly replace standard fibers used in medical devices currently on the market and may enable significantly improved clinical outcomes by delivering sensitive therapeutic agents in controlled, sustained release profiles. Dr. Nelson founded TissueGen in 2000 following his work as a faculty member at University of Texas at Arlington, while simultaneously pursuing development of a fiber-based, biodegradable vascular stent to deliver gene therapy to the vessel wall, as well as drug-loaded microspheres for improved wound healing.
Other webcast participants include:
- Dr. Patrick Anquetil, Chief Executive Officer of Portal Instruments Inc.
- Dr. Joseph Sarret, Chief Business Officer of Corium International
- Dr. Paul Gavin, Chief Scientific Officer of Phosphagenics Limited
- Dr. Roy Farfara, Chief Scientific Officer of TrioxNano
- Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers.
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery. Register here.
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may enable significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the topical or implant site in controlled, sustained release profiles. With localized delivery of pharmaceuticals and biologics, ELUTE fiber may enable medical device developers to guide the body's healing and regenerative processes. For more information, please visit www.tissuegen.com.